Click here - to use the wp menu builder

U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older

January 12, 2021

Newsletters Regulatory Affairs

KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–US FDA Accepts for Priority Review the Biologics License Application for V114 for Use in Adults 18 Years of Age and Older

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles